Publications by authors named "M Bricout"
Article Synopsis
- * Parkinson's disease (PD) patients treated with l-DOPA show some protection against nAMD, but the exact mechanism was unclear until now.
- * Research indicates that l-DOPA enhances dopamine receptor D2 (DRD2) signaling, which may inhibit the harmful growth of blood vessels in the eye, suggesting that DRD2 agonists could be potential complementary treatments for nAMD.
Introduction: Retinal cavernous hemangioma (RCH) is a rare retinal vascular disease characterized by grape-like clusters of saccular aneurysms, usually unilateral, asymptomatic and non-progressive. The diagnosis is made by multimodal imaging including conventional fluorescein angiography (FA). The recent introduction of swept source optical coherence tomography angiography (SS-OCTA) has allowed new insight into vascular diseases, allowing non-invasive, more precise visualization of retinal and choroidal blood flow, and represents a possible alternative to FA.
View Article and Find Full Text PDFPurpose: To assess the feasibility and acceptability of outpatient care without next-day examination for patients undergoing retinal surgery.
Methods: Patients undergoing ambulatory vitreoretinal surgery between November 2013 and February 2016 at the Vienna medical center were included in this retrospective study. The age, comorbidities, indication, surgical technique and type of anesthesia used, symptoms, intraocular pressure and biomicroscopic examination data at the D0, D7 and M1 visits were recorded.
Background: Palmitate in breast milk is predominantly located in the triacylglycerol sn-2 position, while infant formulae contain palmitate predominantly in the sn-1 and sn-3 positions. During digestion, palmitate in the sn-1 and sn-3 positions is hydrolyzed to free palmitic acid that can subsequently complex with calcium to form insoluble soaps; this may partially explain why formula-fed infants have harder stools than breast-fed infants.
Methods: This large (n = 488) randomized, double-blind, multicentre trial investigated whether increasing the sn-2 palmitate content of infant formula improves stool consistency and bone mineral content (measured by dual-energy x-ray absorptiometry), without affecting growth or health.